No fewer than four ADCs with this target start human testing.
ApexOnco Front Page
Recent articles
On a cross-trial basis varegacestat beats Ogsiveo.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
The company will try to get the Komzifti QTc prolongation warning removed.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
It’s less about being fast, more about producing a better product.
